Sponsor
Sanofi-Aventis Australia
72 PBAC submissions on file, active 2005–2025. 65% have been recommended.
Submissions
72
2005 → 2025
Win rate
65 %
46 recommended of 71 bucketable
Drugs
36 · 28 listed
unique molecules submitted
PBS spend captured
$582M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Endocrinology 14 Oncology 12 Vaccines 11 Dermatology 11 Cardiovascular 9 Haematology 3 Neurology 2 Rare disease 2 Respiratory 2 Rheumatology 2
Activity by year 2005 (2) · 2006 (2) · 2007 (5) · 2008 (4) · 2009 (1) · 2010 (2) · 2011 (3) · 2012 (1) · 2013 (3) · 2014 (3) · 2015 (2) · 2016 (1) · 2017 (2) · 2018 (7) · 2019 (8) · 2020 (7) · 2021 (3) · 2022 (5) · 2023 (5) · 2024 (4) · 2025 (2)
Rejection patterns
Across 25 Not recommended decisions on file.
2× high and uncertain cost-effectiveness ratio1× uncertain K-RAS status effect modifier1× modest median OS gain of 1.44 months (PBAC considered 3-5 months meaningful)1× inadequate evidence for non-inferiority to cetuximab in WT K-RAS population due to trial exchangeability limitations1× potential worse comparative safety profileOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.